ClinicalTrials.Veeva

Menu
Willow Rheumatology and Wellness, PLLC | Willowbrook, IL logo

Willow Rheumatology and Wellness, PLLC | Willowbrook, IL

Research site

Site insights

Top conditions

Top treatments

Ianalumab
Upadacitinib
Guselkumab
Ixekizumab
Tirzepatide
Lutikizumab
Obexelimab
Secukinumab
Belimumab
Sarilumab

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Contact this site

Angela R. Crowley, MD, FACR

Verified by this site

Active trials

30 of 38 total trials

A Clinical Study of Tulisokibart (MK-7240) to Treat Radiographic Axial Spondyloarthritis (MK-7240-013)

Researchers are looking for new ways to treat radiographic axial spondyloarthritis (r-axSpA). R-axSpA is a type of arthritis that causes pain, stiffn...

Enrolling
Radiographic Axial Spondyloarthritis
Drug: Placebo
Drug: Tulisokibart

The primary objective of this trial is to evaluate the effect of pegloticase 18 mg subcutaneously (SC) every two weeks with methotrexate (MTX) versus...

Enrolling
Uncontrolled Gout
Drug: Pegloticase
Drug: Methotrexate

To evaluate efficacy, safety, and tolerability of DDY391 up to 52 weeks in participants with Sjögren's disease (SjD) and to determine the dose respon...

Enrolling
Sjögren's Disease
Drug: Placebo
Drug: DDY391
Locations recently updated

This is a prospective, open-label, single arm 3-year clinical study to describe the short-term and long-term efficacy and safety of belimumab in part...

Active, not recruiting
Systemic Lupus Erythematosus
Biological: Belimumab (GSK1550188)

The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) axial disease by...

Active, not recruiting
Arthritis, Psoriatic
Drug: Placebo
Drug: Guselkumab

The purpose of this study is to evaluate how well nipocalimab works as compared to placebo in participants with moderate to severe Systemic lupus ery...

Enrolling
Lupus Erythematosus, Systemic
Drug: Nipocalimab
Drug: Standard of care treatment

This study aims to examine the efficacy and safety of obexelimab in participants with systemic lupus erythematosus (SLE).

Active, not recruiting
Systemic Lupus Erythematosus
Drug: Placebo
Drug: Obexelimab

This is a multi-center, double-blind, placebo-controlled, Phase 2, proof-of-concept basket study with the goal of assessing the efficacy and safety o...

Active, not recruiting
AxSpA
PsA (Psoriatic Arthritis)
Drug: Placebo
Drug: SPY002-072

The main purpose of the proposed study is to evaluate the efficacy of efgartigimod PH20 SC in patients with moderate-to-severe Primary Sjögren's Dise...

Active, not recruiting
Primary Sjogrens Disease
Biological: Efgartigimod PH20 SC
Other: Placebo PH20 SC

This study will assess the efficacy and safety of Afimkibart (also known as RO7790121) compared with placebo in participants with moderate to severe...

Enrolling
Rheumatoid Arthritis
Drug: Placebo
Drug: Afimkibart

Rheumatoid Arthritis (RA) is a chronic inflammatory disease causing pain, stiffness, swelling and loss of joint function. This study will evaluate th...

Enrolling
Rheumatoid Arthritis
Drug: Lutikizumab
Drug: Placebo

The purpose of this study is to evaluate the ability of dapirolizumab pegol (DZP) as an add-on treatment to standard of care (SOC) medication to achi...

Enrolling
Systemic Lupus Erythematosus
Drug: DZP
Other: Placebo

The purpose of this study is to evaluate the efficacy of icotrokinra compared to placebo in participants with active psoriatic arthritis (PsA) by ass...

Active, not recruiting
Arthritis, Psoriatic
Drug: Placebo
Drug: Active reference comparator

The purpose of this study is to evaluate how well the study drug JNJ-88545223 works compared with a placebo (an inactive substance) in adults with ac...

Enrolling
Arthritis, Psoriatic
Drug: Placebo
Drug: JNJ-88545223

The purpose of the SUNFLOWER study is to describe clinical outcomes, including DORIS remission, achieved following the initiation of anifrolumab 120...

Enrolling
Systemic Lupus Erythematosus
Drug: Anifrolumab

The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participan...

Active, not recruiting
Overweight or Obesity
Psoriatic Arthritis
Drug: Tirzepatide

Phase II study in participants with moderately-to-severely active rheumatoid Arthritis (RA) to evaluate efficacy and safety of AZD1163.

Enrolling
Rheumatoid Arthritis
Drug: AZD1163
Other: Placebo

The purpose of this multicenter, randomized, placebo-controlled and double-blind study is to evaluate the efficacy and safety of subcutaneous anifrol...

Enrolling
Polymyositis, Dermatomyositis
Combination Product: Anifrolumab (unblinded, open label)
Combination Product: Anifrolumab (blinded)

A Basket Trial of Refractory Rheumatoid Arthritis (RA), Sjögren's Disease (SjD), Idiopathic Inflammatory Myopathies (IIMs) and Systemic Sclerosis (SS...

Enrolling
Myositis
Refractory Rheumatoid Arthritis (RA)
Drug: Allogeneic NK Cells

The trial is an open-label randomized study that will examine whether switching to a selective IL23 inhibitor (guselkumab) is more effective than swi...

Enrolling
Psoriatic Arthritis
Drug: Guselkumab
Drug: Golimumab

Trial sponsors

Novartis logo
Janssen (J&J Innovative Medicine) logo
AbbVie logo
Lilly logo
AstraZeneca logo
Amgen logo
S
A
Bristol-Myers Squibb (BMS) logo
GlaxoSmithKline (GSK) logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems